Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1

BACKGROUND: Treatment failure is a critical issue in breast cancer and identifying useful interventions that optimize current cancer therapies remains a critical unmet need. Expression and functional studies have identified connexins (Cxs), a family of gap junction proteins, as potential tumor suppr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grek, Christina L, Rhett, Joshua Matthew, Bruce, Jaclynn S, Abt, Melissa A, Ghatnekar, Gautam S, Yeh, Elizabeth S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407347/
https://www.ncbi.nlm.nih.gov/pubmed/25881004
http://dx.doi.org/10.1186/s12885-015-1229-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407347/
https://www.ncbi.nlm.nih.gov/pubmed/25881004
http://dx.doi.org/10.1186/s12885-015-1229-6

Ejemplares similares